These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 35639961)
1. A methylation-driven genes prognostic signature and the immune microenvironment in epithelial ovarian cancer. Tan M; Wang S; Li F; Xu H; Gao J; Zhu L Carcinogenesis; 2022 Aug; 43(7):635-646. PubMed ID: 35639961 [TBL] [Abstract][Full Text] [Related]
2. A prognostic model based on immune-related long noncoding RNAs for patients with epithelial ovarian cancer. Peng Y; Wang H; Huang Q; Wu J; Zhang M J Ovarian Res; 2022 Jan; 15(1):8. PubMed ID: 35031063 [TBL] [Abstract][Full Text] [Related]
3. Acetylation model predicts prognosis of patients and affects immune microenvironment infiltration in epithelial ovarian carcinoma. Wang X; Li X; Wei L; Yu Y; Hazaisihan Y; Tao L; Jia W J Ovarian Res; 2024 Jul; 17(1):150. PubMed ID: 39030559 [TBL] [Abstract][Full Text] [Related]
4. Multi-omics analysis of tumor mutational burden combined with prognostic assessment in epithelial ovarian cancer based on TCGA database. Liu J; Xu W; Li S; Sun R; Cheng W Int J Med Sci; 2020; 17(18):3200-3213. PubMed ID: 33173439 [No Abstract] [Full Text] [Related]
5. Identification of a prognostic signature of epithelial ovarian cancer based on tumor immune microenvironment exploration. Liu J; Meng H; Nie S; Sun Y; Jiang P; Li S; Yang J; Sun R; Cheng W Genomics; 2020 Nov; 112(6):4827-4841. PubMed ID: 32890701 [TBL] [Abstract][Full Text] [Related]
6. Identification and Verification of Necroptosis-Related Gene Signature With Prognosis and Tumor Immune Microenvironment in Ovarian Cancer. Wang Z; Chen G; Dai F; Liu S; Hu W; Cheng Y Front Immunol; 2022; 13():894718. PubMed ID: 35812403 [TBL] [Abstract][Full Text] [Related]
7. Epigenomic Profiling of Epithelial Ovarian Cancer Stem-Cell Differentiation Reveals GPD1 Associated Immune Suppressive Microenvironment and Poor Prognosis. Chen LY; Huang RL; Su PH; Chu LH; Weng YC; Wang HC; Lai HC; Wen KC Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563509 [TBL] [Abstract][Full Text] [Related]
8. The Comprehensive Analysis of Interferon-Related Prognostic Signature with regard to Immune Features in Ovarian Cancer. An Y; Duan H Dis Markers; 2022; 2022():7900785. PubMed ID: 35769811 [TBL] [Abstract][Full Text] [Related]
9. CAMK2N1/RUNX3 methylation is an independent prognostic biomarker for progression-free and overall survival of platinum-sensitive epithelial ovarian cancer patients. Heinze K; Rengsberger M; Gajda M; Jansen L; Osmers L; Oliveira-Ferrer L; Schmalfeldt B; Dürst M; Häfner N; Runnebaum IB Clin Epigenetics; 2021 Jan; 13(1):15. PubMed ID: 33482905 [TBL] [Abstract][Full Text] [Related]
10. Systematic Construction and Validation of an Immune-Related Gene-Based Model to Predict Prognosis for Ovarian Cancer. Fu Y; Sun H Biomed Res Int; 2022; 2022():7356992. PubMed ID: 35496047 [TBL] [Abstract][Full Text] [Related]
11. N6-Methyladenosine-Related RNA Signature Predicting the Prognosis of Ovarian Cancer. Jiao J; Jiang L; Luo Y Recent Pat Anticancer Drug Discov; 2021; 16(3):407-416. PubMed ID: 34137363 [TBL] [Abstract][Full Text] [Related]
12. Clinical associations between ASCT2 and p‑mTOR in the pathogenesis and prognosis of epithelial ovarian cancer. Guo H; Xu Y; Wang F; Shen Z; Tuo X; Qian H; Wang H; Wang K Oncol Rep; 2018 Dec; 40(6):3725-3733. PubMed ID: 30272366 [TBL] [Abstract][Full Text] [Related]
13. Identification and validation of a gene-based signature reveals SLC25A10 as a novel prognostic indicator for patients with ovarian cancer. Li QJ; Wang J; Jiang J; Lin B J Ovarian Res; 2022 Sep; 15(1):106. PubMed ID: 36114504 [TBL] [Abstract][Full Text] [Related]
14. DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer. Zhang W; Barger CJ; Link PA; Mhawech-Fauceglia P; Miller A; Akers SN; Odunsi K; Karpf AR Epigenetics; 2015; 10(8):736-48. PubMed ID: 26098711 [TBL] [Abstract][Full Text] [Related]
15. Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial‑mesenchymal transition. Lu DH; Yang J; Gao LK; Min J; Tang JM; Hu M; Li Y; Li ST; Chen J; Hong L Oncol Rep; 2019 Feb; 41(2):917-927. PubMed ID: 30483796 [TBL] [Abstract][Full Text] [Related]
16. Upregulation of lncRNA AB073614 functions as a predictor of epithelial ovarian cancer prognosis and promotes tumor growth in vitro and in vivo. Zeng S; Liu S; Feng J; Gao J; Xue F Cancer Biomark; 2019; 24(4):421-428. PubMed ID: 30909184 [TBL] [Abstract][Full Text] [Related]
17. Establishment of a novel glycolysis-related prognostic gene signature for ovarian cancer and its relationships with immune infiltration of the tumor microenvironment. Bi J; Bi F; Pan X; Yang Q J Transl Med; 2021 Sep; 19(1):382. PubMed ID: 34496868 [TBL] [Abstract][Full Text] [Related]
18. Identification of epigenetic genes for predicting prognosis and immunotherapy response of ovarian cancer. Shen W; Jiang W; Ye S; Sun M; Yang H; Shan B Jpn J Clin Oncol; 2022 Jul; 52(7):742-751. PubMed ID: 35435215 [TBL] [Abstract][Full Text] [Related]
19. Molecular Signature for Lymphatic Invasion Associated with Survival of Epithelial Ovarian Cancer. Paik ES; Choi HJ; Kim TJ; Lee JW; Kim BG; Bae DS; Choi CH Cancer Res Treat; 2018 Apr; 50(2):461-473. PubMed ID: 28546526 [TBL] [Abstract][Full Text] [Related]
20. Identification and verification of a ten-gene signature predicting overall survival for ovarian cancer. Liu J; Xu F; Cheng W; Gao L Exp Cell Res; 2020 Oct; 395(2):112235. PubMed ID: 32805252 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]